About this trial
Low-dose aspirin (LDA) is considered to be the most effective agent to prevent preeclampsia (PE). At present, there is little exploration about the timing of aspirin discontinuation. Most international guidelines default until 36 weeks of gestation or delivery. China Guideline (2020) recommended that aspirin should be preventively used until 26-28 weeks of gestation, but there was little direct evidence. According to the two-stage theory, placental dysplasia before 28 weeks of gestation is the key to developing PE, the significance of aspirin use after 28 weeks of gestation is debatable. If aspirin discontinuation at 28 weeks of gestation is proven to be feasible for preventing preterm PE, it will not only reduce the risk of Perinatal Haemorrhage but also save medical expenses.
Eligibility criteria
Qualifiers
At <16 weeks of gestation, normal NT scan
At least 1 high risk factor or at least 2 moderate risk factors
Intend to receive prenatal examination and deliver in this institution
Signed a written informed consent for participation in the study
Disqualifiers
Aspirin initiated after 16 week
Intolerant or allergic to aspirin
Aspirin adherence was <80%
Miscarriage or termination of pregnancy before randomization
Trial design
Treatments tested in this trial
- aspirin discontinuation
- aspirin continuation
Treatment groups
Sponsors and collaborators
FANG HE
Lead sponsor
The Third Affiliated Hospital of Guangzhou Medical University
Sponsor institution